Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $154.0, along ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a recent deep-dive research report on the state of the ...

Looking at DexCom, new customer additions are leading the revenue growth, amid rising awareness of CGM devices. DexCom is ...

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM. Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.

Let's consider two such stocks: Moderna ( MRNA 7.13%) and DexCom ( DXCM -1.65%). These two healthcare companies have lagged ...

Leerink Partners analyst Mike Kratky maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

Dexcom (Nasdaq:DXCM) announced today that it launched the Dexcom ONE+ continuous glucose monitor (CGM) in the UK.

The Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 continuous glucose monitoring systems (CGMs).

More time in closed loop with Dexcom G7’s 30-minute sensor warm-up time – faster than any other CGM on the market. 5 Additional discretion with Dexcom G7’s low-profile, all-in-one wearable.